K-Ras G12C-IN-3 is a mutant KRAS G12C ligand designed to engage the covalent pocket associated with the cysteine-containing mutant protein. This class of ligand provides a target-recognition element for exploring KRAS G12C-directed PROTAC or degrader-like strategies. In a bifunctional design, the KRAS G12C-binding moiety can be linked to an E3 ligase recruiter through an attachment site that preserves mutant-selective engagement while supporting proximity to ubiquitination machinery. The desired mechanism is ternary complex formation, mutant KRAS ubiquitination, and proteasome-dependent protein depletion. Such molecules can help researchers evaluate whether degradation of KRAS G12C produces signaling effects distinct from covalent pocket occupancy alone. K-Ras G12C-IN-3 is useful for mutant RAS chemical biology, degrader feasibility studies, linker optimization, target engagement assays, and development of selective tools for oncogenic KRAS pathway research.
Structure of 1629268-19-4
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: This ligand targets KRAS G12C mutant protein in biochemical or cellular target-engagement studies.
Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for KRAS G12C mutant protein. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings KRAS G12C mutant protein into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.
Applications• PROTAC-Mediated K-Ras Degradation: Use K-Ras G12C-IN-3 as a targeting ligand within PROTAC designs to recruit E3 ligases toward the G12C mutant state. This enables systematic evaluation of ternary complex formation, ubiquitination efficiency, and proteasome-dependent loss of K-Ras, supporting mechanism-of-action studies in Ras-driven signaling contexts.
• E3 Ligase Recruitment Optimization: Incorporate K-Ras G12C-IN-3 into PROTAC scaffolds to compare different E3 ligase recruiters and linker geometries. By tuning spatial orientation and binding kinetics, researchers can map degradation potency versus target engagement, identify effective ternary complex cooperativity, and optimize conditions for robust, selective degradation of G12C-bearing cells.
• Structure-Guided PROTAC Design: Apply structural and biophysical insights from K-Ras G12C-IN-3 binding to design PROTACs with improved compatibility at the mutant pocket. This direction supports rational linker placement, assessment of steric constraints, and refinement of binding modes to enhance ubiquitin transfer and accelerate proteolysis of K-Ras G12C.
• Pathway Suppression Mechanism Studies: Deploy K-Ras G12C-IN-3-based PROTACs to interrogate how selective degradation of mutant K-Ras reshapes downstream signaling. Researchers can correlate degradation kinetics and extent with changes in RAF/MEK/ERK and related pathways, distinguishing degradation-driven effects from occupancy-only outcomes and validating degradation specificity.
| ConcentrationVolumeMass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.2039 mL | 11.0193 mL | 22.0386 mL |
| 5 mM | 0.4408 mL | 2.2039 mL | 4.4077 mL |
| 10 mM | 0.2204 mL | 1.1019 mL | 2.2039 mL |
K-Ras G12C-IN-3 is a KRAS G12C ligand-like scaffold containing an acrylamide covalent warhead. It may support KRAS G12C-directed degrader design if the warhead remains accessible.
Structure: K-Ras G12C-IN-3 is a KRAS G12C ligand-like scaffold containing a dichlorinated biaryl region, methoxy substituent, piperazine carboxamide, and an acrylamide electrophilic warhead. The acrylamide is the key covalent-reactive feature, while the chlorinated aryl rings provide hydrophobic recognition elements.
Reactivity: For KRAS G12C-directed PROTAC design, the acrylamide warhead should be preserved and not used as the linker attachment point because it is required for covalent cysteine engagement. Linker installation should be explored from the piperazine or amide-associated vector in a designed analog. Alkyl, PEG, amide, carbamate, or piperazine-compatible linkers can be paired with CRBN, VHL, or IAP ligands while maintaining warhead accessibility and KRAS-binding orientation.
Can you provide the solubility of K-Ras G12C-IN-3 ?
Sure. The solubility of K-Ras G12C-IN-3 (CAS 1629268-19-4) in DMSO is ≥ 30 mg/mL (66.12 mM). This means that 30 milligrams of K-Ras G12C-IN-3 can be dissolved in 1 milliliter of DMSO.
9/11/2018
Do you know does K-Ras G12C-IN-3 biosynthesized monorhamnolipids?
No, K-Ras G12C-IN-3 does not biosynthesize monorhamnolipids.K-Ras G12C-IN-3 is a small molecule drug that is not produced by bacteria.
6/6/2019
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.